Persica Pharmaceuticals has completed the first stage of its clinical trial on a unique injectable, PP353, to treat chronic lower back pain Novel approach applicable to 20% of all CLBP populations First therapy to directly address a cause of CLBP in Modic 1 subgroup of patients Uniquely for a First in Human CLBP trial there is already clinical proof of